Advancing cancer care
through
microbiome profiling
Discover more
BiomeOne is now available in 8 languages!
After years of research and development, BiomeDx® has launched its first diagnostic tool in early 2022. BiomeOne® is the world’s first stool-based prediction test for immunotherapy (ICI) response.
The field of oncology has been revolutionized by the introduction of immune checkpoint inhibitors. However, many patients still do not benefit from cancer immunotherapy, or worse, suffer serious immune-related side effects. We provide a single microbial signature that predicts whether cancer immunotherapy is potentially beneficial and how probable side effects might be.
About BiomeDx
Biome Diagnostics (BiomeDx) is an Austrian MedTech company founded with the mission to advance precision medicine by providing healthcare professionals with world-class microbiome diagnostic tools.
Safety and health of patients are our top priorities! To ensure top level quality and safety, we certified according to ISO 9001 (quality management systems) and ISO 13485 (medical devices). BiomeDx is globally the first company in the area of microbiome that holds both ISO certifications.
We combine intestinal microbiome analysis with advanced machine learning techniques
Our advanced analysis platform combines a proprietary knowledge database and thousands of samples with advanced bioinformatics, statistical models and machine learning algorithms. Together with cutting edge metagenomic sequencing technologies we are able to identify thousands of bacterial organisms and predict their activities and roles in immune related functions within the body.
Supported by
